abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

هذه الصفحة غير متوفرة باللغة العربية وهي معروضة باللغة English

رد الشركة

9 يناير 2015

الكاتب:
Gilead Sciences

Gilead Sciences' Response

إظهار جميع الإشارات

...Gilead Sciences is working to help ensure access to its chronic hepatitis C medicines for all patients who can benefit from them. The company is... working with national governments to provide its branded medicines...As part of these efforts Gilead and its partners are designing measures to ensure that these high value curative medicines are not diverted...

Read full response here

الجدول الزمني